Use of polyamine derivatives as selective histone deacetylase inhibitors

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Histone acetylation and deacetylation regulate gene expression, with histone deacetylases (HDACs) playing a critical role.
• HDAC inhibitors are utilized in cancer therapy to re-express silenced tumor suppressor genes.
• The specific HDAC isoforms involved in human cancers remain largely undetermined.

Purpose of the Study:

• To design and synthesize novel polyaminohydroxamic acid (PAHA) and polyaminobenzamide (PABA) compounds as selective HDAC inhibitors.
• To investigate the isoform-specific inhibition profiles of these novel compounds against four HDAC isoforms.
• To evaluate the cellular effects, including tumor suppressor gene re-expression and histone hyperacetylation, induced by these inhibitors.

Main Methods:

• Synthesis of PAHA and PABA compounds.
• Quantification of global and isoform-specific HDAC inhibition.
• Measurement of tumor suppressor protein re-expression and histone H3/H4 hyperacetylation.
• Assessment of cellular effects: growth stimulation, cytostasis, and cytotoxicity.
• Evaluation of polyamine transport system utilization and annexin A1 induction.

Main Results:

• Developed PAHA and PABA compounds exhibiting selectivity among four HDAC isoforms.
• Active inhibitors successfully promoted tumor suppressor factor re-expression.
• Variable cellular responses observed, including growth stimulation, cytostasis, and cytotoxicity.
• Demonstrated ability of PAHAs and PABAs to utilize the polyamine transport system.
• Induction of early apoptotic factor annexin A1 overexpression was observed.

Conclusions:

• Novel PAHA and PABA compounds are effective HDAC inhibitors with isoform selectivity.
• These inhibitors can re-express tumor suppressor genes, leading to diverse cellular outcomes in cancer contexts.
• Further investigation into the mechanisms and therapeutic potential of these selective HDAC inhibitors is warranted.